{"id":"W2557666746","doi":"10.1016/s1470-2045(16)30559-9","title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1200,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"Cancer Research UK; Clovis Oncology; Ovarian Cancer Research Fund; Stand Up To Cancer; Healthway; U.S. Department of Defense; National Ovarian Cancer Coalition; Ovarian Cancer Research Fund Alliance; American Association for Cancer Research","keywords":"Open label; Oncology; Medicine; Internal medicine; Ovarian carcinoma; Platinum; Ovarian cancer; Clinical trial; Cancer; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001909533,0.001609643,0.00255087,0.0003915906,0.0003098634,0.001237936,0.001014195,0.00162487,0.00538216],"category_scores_gemma":[0.001335877,0.0004909491,0.00176682,0.000427501,0.000804156,0.001336128,0.0004292531,0.004622358,0.001436219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008122993,"about_ca_system_score_gemma":0.0008818129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007909434,"about_ca_topic_score_gemma":0.002456791,"domain_scores_codex":[0.9995245,0.000211317,0.00001566193,0.00009241849,0.0000408014,0.0001154514],"domain_scores_gemma":[0.9993293,0.0001556494,0.0001106707,0.00007922612,0.00003442714,0.0002907613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7911469,0.02008582,0.002915731,0.00203434,0.003061134,0.0002713131,0.0002371805,0.00319819,0.01400797,0.0006323219,0.01104237,0.1513667],"study_design_scores_gemma":[0.8638442,0.1216533,0.005008267,0.00007965576,0.0007378084,0.0003404723,0.00006198061,0.001567659,0.001767188,0.0004324607,0.004457132,0.00004980301],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9757085,0.0117281,0.0009870726,0.001553231,0.0004880175,0.001767965,0.00268218,0.0004064905,0.004678438],"genre_scores_gemma":[0.9743536,0.005971343,0.00223648,0.00253569,0.0004154857,0.002053814,0.005393807,0.0001087022,0.006931029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00538216,"threshold_uncertainty_score":0.01800507,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1468834883678543,"score_gpt":0.4311228869311657,"score_spread":0.2842393985633114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}